Vium Appoints Wendel Barr as CEO

Vium, a living informatics platform for preclinical in vivo drug research, today announced that its board of directors has appointed Wendel Barr as chief executive officer (CEO).

Before joining Vium, Barr worked at clinical contract research organization (CRO) SynteractHCR, where he served as CEO and board member for more than six years. Prior to SynteractHCR, Barr was at global CRO Covance for 10 years, serving as chief operating officer and executive vice president for the last three years of his tenure.

“As Vium continues to seize significant commercial opportunities with its novel digital approach to discovery and translational science, we have attracted accomplished senior leaders to deliver on the promise of the platform,” said Dr. Annalisa Jenkins, executive chairman of the Vium board of directors. “We’re thrilled to have recruited Wendel Barr to apply his deep industry expertise, which will allow Vium to pursue the most promising growth opportunities.”